reports
DocMorris continues to grow in the first quarter of 2024 and creates d...
DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market 16.04.2024 / 06:57 CET/CEST Frauenfeld, 16 April 2024 Press release DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market Revenue development as planned in the first quarter with growth of 10.3 per cent Positive indications for e-prescription market share Successful completion of the Germany-wide rollout of fully digital e-presc...
DocMorris setzt Wachstumskurs im ersten Quartal 2024 fort und schafft ...
DocMorris AG / Schlagwort(e): Quartals-/Zwischenmitteilung DocMorris setzt Wachstumskurs im ersten Quartal 2024 fort und schafft digitalen Zugang zum gesamten E-Rezept-Markt 16.04.2024 / 06:57 CET/CEST Frauenfeld, 16. April 2024 Medienmitteilung DocMorris setzt Wachstumskurs im ersten Quartal 2024 fort und schafft digitalen Zugang zum gesamten E-Rezept-Markt Planmässige Umsatzentwicklung im ersten Quartal mit Wachstum von 10.3 Prozent Positive Indikationen beim E-Rezept-Marktanteil Erfolgreicher Abschluss des deutschlandweiten Rollouts der volldigitalen E-Rezept-Einlö...
- ABGSC Construct. & Real Estate Research
- Bengt Jonassen
- Njål Kleiven
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive ...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment April 16, 2024 – 7:00am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, ...
Letenda va équiper ses bus électriques zéro émission avec les systèmes...
PARIS--(BUSINESS WIRE)-- Regulatory News: Forsee Power (FR0014005SB3 – FORSE), l’expert en systèmes de batteries intelligents pour l'électromobilité durable, et Letenda, constructeur canadien de bus zéro émission, annoncent que les bus innovants zéro émission Electrip de Letenda seront équipés de systèmes de batteries Forsee Power. Forsee Power fournira ses systèmes de batteries hautes énergie ZEN PLUS qui seront installés sur les véhicules spécialement conçus pour la propulsion électrique. Electrip by Letenda est présenté à l'occasion de l'Ontario Transportation Expo au Canada du 15 au 17...
Construction contract in Lithuania (increase in the volume of design-b...
Construction contract in Lithuania (increase in the volume of design-build contract) On 15. April 2024, the addendum to the design-build contract between UAB Merko Statyba, part of AS Merko Ehitus group, and North Atlantic Treaty Organization (NATO) Support and Procurement Agency entered into force for additional works on the construction of new infrastructures of the training center in Pabrade, Lithuania. The value of additional works exceeds EUR 20 million, plus the applicable value added tax. The actual value is determined after adjustment with the construction price index of the re...
Ehitusleping Leedus (projekteerimis-ehituslepingu mahu suurenemine)
Ehitusleping Leedus (projekteerimis-ehituslepingu mahu suurenemine) 15. aprillil 2024 jõustus AS Merko Ehitus kontserni kuuluv UAB Merko Statyba ning Põhja-Atlandi Lepingu Organisatsiooni (NATO) toetus- ja hankeameti vahelise projekteerimis-ehituslepingu lisa täiendavateks töödeks väljaõppekeskuse uute taristute ehitamisel Pabrades, Leedus. Täiendavate tööde maksumus ületab 20 miljonit eurot, millele lisandub kohalduv käibemaks. Tegelik maksumus selgub vastavate perioodide ehitushinnaindeksiga korrigeerimise järel. Tööde valmimise tähtaeg on 2026. aasta alguses. UAB Merko Statyba...
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results ...
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Halle (Saale) / Munich, Germany, April 16, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its financial results for the full ...
VGP and Deka Immobilien Complete Second Closing in 50:50 ‘RED’ Joint ...
VGP and Deka Immobilien Complete Second Closing in 50:50 ‘RED’ Joint Venture PRESS RELEASE Regulated Information Antwerp, Belgium, 16 April 2024 (7.00 a.m. CET) VGP NV ('VGP') and Deka Immobilien, one of the largest globally active real estate investment companies in Europe, today announced the signing of the second closing between VGP and their 50:50 joint venture, RED (The ‘Fifth Joint Venture’). The transaction comprises two logistics buildings and a multi-storey car park which were developed in parks that have already transferred to the joint venture in the first closing. At t...
VGP en Deka Immobilien Voltooien Tweede Closing in 50:50 'RED' Joint V...
VGP en Deka Immobilien Voltooien Tweede Closing in 50:50 'RED' Joint Venture PERSBERICHT Gereglementeerde informatie Antwerpen, België, 16 april 2024 (7.00 uur CET) VGP NV ('VGP') en Deka Immobilien, één van Europa’s grootste, wereldwijd actieve vastgoedinvesteringsmaatschappijen, kondigen vandaag de ondertekening aan van de tweede closing tussen VGP en hun 50:50 joint venture RED (de 'Vijfde Joint Venture'). De transactie omvat twee logistieke gebouwen en een parkeergarage die op het moment van de eerste closing nog in aanbouw waren en inmiddels werden voltooid. De gebouwen zij...
- ABGSC Construct. & Real Estate Research
- Bengt Jonassen
- Njål Kleiven
- ABGSC Construct. & Real Estate Research
- Bengt Jonassen
- Njål Kleiven
- ABGSC Construct. & Real Estate Research
- Bengt Jonassen
- Njål Kleiven
Science Applications International Corp: 3 directors
Three Directors at Science Applications International Corp bought 3,895 shares at between 125.750USD and 126.040USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the ...
Moody's Ratings downgrades ratings of Greenland Hong Kong; outlook neg...
Moody's Ratings has downgraded the corporate family rating (CFR) of Greenland Hong Kong Holdings Limited to Ca from Caa2. At the same time, Moody's Ratings has downgraded the following ratings: • The backed senior unsecured rating on Greenland Hong Kong Holdings Limited's MTN program to (P)C fro...
- Felix Fischer
Lucror Analytics - Morning Views Europe
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar. To request full and unrestricted access to Lucror’s research and analytics platform, please visit
- ABGSC Construct. & Real Estate Research
- Bengt Jonassen
- Njål Kleiven
- ABGSC Construct. & Real Estate Research
- Bengt Jonassen
- Njål Kleiven
- ABGSC Construct. & Real Estate Research
- Bengt Jonassen
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.